“Vasculitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Vasculitis Market.

The Vasculitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Vasculitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Vasculitis treatment therapies with a considerable amount of success over the years. 
• Vasculitis companies working in the treatment market are Ambulero, Beijing Defengrei Biotechnology, Janssen Biotech, Novartis, AbbVie, Visterra, InflaRx, and others, are developing therapies for the Vasculitis treatment 

• Emerging Vasculitis therapies in the different phases of clinical trials are- AMB 301, BDB 1, Guselkumab, Secukinumab, Upadacitinib, Research program:Kidney Disorder Therapeutics, Vilobelimab, and others are expected to have a significant impact on the Vasculitis market in the coming years.   
• In October 2021, In order to compare the effectiveness and safety of Secukinumab 300 mg administered subcutaneously in comparison to placebo, in conjunction with a glucocorticoid taper regimen, in patients with Giant Cell Arthritis (GCA), Novartis Pharmaceuticals started a randomised, parallel group, double blind, placebo controlled multicenter Phase III trial. This phase III research compares secukinumab to a placebo in terms of effectiveness and safety when used in conjunction with a glucocorticoid taper regimen for patients with giant cell arteritis (GCA).
• Following FDA approval on October 8, 2021, Chemocentryx introduced TAVNEOS in the fourth quarter of 2021 as an adjunctive therapy for adult patients with severe active ANCA-associated vasculitis, specifically granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main types of ANCA-associated vasculitis, in combination with standard therapy, including glucocorticoids.
• In January 2022, the European Union (EU) granted ChemoCentryx clearance to market Tavneos (avacopan), a medication used to treat adult patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis).
• In November 2021, Positive results from the first-in-class anti-C5a antibody vilobelimab’s European Phase II IXCHANGE study in people with ANCA-associated vasculitis (AAV) were released by InflaRx. The study’s main goal was accomplished by showing that vilobelimab had a clinical response that is comparable to that of the standard of care while also dramatically reducing the requirement for glucocorticoid (GC) therapy.
• In November 2021, In order to treat Buerger’s Disease (BD), also known as Thromboangiitis Obliterans (TAO), Ambulero’s gene therapy candidate, AMB-301, received approval from the U.S. FDA’s Office for Orphan Products Development (OOPD) to be classified as an orphan drug.
• A Phase III clinical trial is investigating the JAK1 selective inhibitor upadacitinib (ABT-494) for the treatment of giant cell arteritis.
• A novel investigational pharmaceutical candidate called Sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is now in the Phase II stage of research.

Vasculitis Overview

The term “vasculitis” refers to a set of uncommon disorders that cause blood vessel inflammation. Veins and arteries are among these vessels. Vasculitis comes in a variety of forms, each with its own set of symptoms, degree of severity, and time course. Vasculitis comes in a variety of unusual forms, and the causes are mostly unknown.

Get a Free Sample PDF Report to know more about Vasculitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/vasculitis-pipeline-insight

Emerging Vasculitis Drugs Under Different Phases of Clinical Development Include:

• AMB 301: Ambulero
• BDB 1: Beijing Defengrei Biotechnology
• Guselkumab: Janssen Biotech
• Secukinumab: Novartis
• Upadacitinib: AbbVie
• Research program:Kidney Disorder Therapeutics: Visterra
• Vilobelimab: InflaRx

Vasculitis Route of Administration

Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Subcutaneous
• Intravenous
• Intramuscular

Vasculitis Molecule Type

Vasculitis Products have been categorized under various Molecule types, such as

• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy 

Vasculitis Pipeline Therapeutics Assessment

• Vasculitis Assessment by Product Type
• Vasculitis By Stage and Product Type
• Vasculitis Assessment by Route of Administration
• Vasculitis By Stage and Route of Administration
• Vasculitis Assessment by Molecule Type
• Vasculitis by Stage and Molecule Type

DelveInsight’s Vasculitis Report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Vasculitis product details are provided in the report. Download the Vasculitis pipeline report to learn more about the emerging Vasculitis therapies

Some of the key companies in the Vasculitis Therapeutics Market include:

Key companies developing therapies for Vasculitis are – CytoDyn, ChemoCentryx, Hoffman-la-Roche, GlaxoSmithKline, Vifor Pharma, R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, Oxitope Pharma, InflaRx, Eli Lilly and company, Toleranzia, Travere Therapeutics, Caladrius Biosciences, Caladrius Biosciences, Yake Biotechnology, and others.

Vasculitis Pipeline Analysis:

The Vasculitis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Vasculitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vasculitis Treatment.
• Vasculitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Vasculitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vasculitis market.
• The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Vasculitis drugs and therapies

Vasculitis Pipeline Market Drivers

• Rising incidence of Vasculitis, the surge in R&D on the treatment of Vasculitis, technological advancement in the diagnostic kits are some of the important factors that are fueling the Vasculitis Market.

Vasculitis Pipeline Market Barriers

• However, side effects caused by the current treatment methods, lack of trained professionals and stringent governmental regulations for Vasculitis drugs and other factors are creating obstacles in the Vasculitis Market growth.

Scope of Vasculitis Pipeline Drug Insight    

• Coverage: Global
• Key Vasculitis Companies: Ambulero, Beijing Defengrei Biotechnology, Janssen Biotech, Novartis, AbbVie, Visterra, InflaRx, and others
• Key Vasculitis Therapies: AMB 301, BDB 1, Guselkumab, Secukinumab, Upadacitinib, Research program:Kidney Disorder Therapeutics, Vilobelimab, and others
• Vasculitis Therapeutic Assessment: Vasculitis current marketed and Vasculitis emerging therapies
• Vasculitis Market Dynamics: Vasculitis market drivers and Vasculitis market barriers 

Request for Sample PDF Report for Vasculitis Pipeline Assessment and clinical trials

Table of Contents

1. Vasculitis Report Introduction

2. Vasculitis Executive Summary

3. Vasculitis Overview

4. Vasculitis- Analytical Perspective In-depth Commercial Assessment

5. Vasculitis Pipeline Therapeutics

6. Vasculitis Late Stage Products (Phase II/III)

7. Vasculitis Mid Stage Products (Phase II)

8. Vasculitis Early Stage Products (Phase I)

9. Vasculitis Preclinical Stage Products

10. Vasculitis Therapeutics Assessment

11. Vasculitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Vasculitis Key Companies

14. Vasculitis Key Products

15. Vasculitis Unmet Needs

16 . Vasculitis Market Drivers and Barriers

17. Vasculitis Future Perspectives and Conclusion

18. Vasculitis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services